Literature DB >> 21985978

Molecular pathogenesis of primary hyperparathyroidism.

F Cetani1, E Pardi, S Borsari, C Marcocci.   

Abstract

Primary hyperparathyroidism (PHPT) is a common endocrinopathy, mostly caused by a monoclonal parathyroid adenoma. The hereditary syndromes include multiple endocrine neoplasia types 1 (MEN 1) and 2A (MEN 2A), hereditary hyperparathyroidism-jaw tumor (HPTJT), familial isolated hyperparathyroidism (FIHP), familial hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHPT). Mutations of MEN1 and CDKN1B genes are responsible for MEN 1 in 70-80% and about 2% of cases, respectively. MEN1 and CDKN1B genes have also a role in the pathogenesis of sporadic parathyroid adenomas. HRPT2/CDC73 gene mutations are responsible for HPT-JT and sporadic parathyroid carcinoma. MEN1 and HRPT2/CDC73 genes mutations have also been found in a subset of FIHP families. FHH and NSHPT represent the mildest and severest variants of PHPT, caused by heterozygous and homozygous mutations in the calcium sensing receptor (CASR) gene, respectively.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21985978

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  11 in total

1.  Proteomics Analysis of Tissue Samples Reveals Changes in Mitochondrial Protein Levels in Parathyroid Hyperplasia over Adenoma.

Authors:  Gurler Akpinar; Murat Kasap; Nuh Zafer Canturk; Mehin Zulfigarova; Eylül Ece Islek; Sertac Ata Guler; Turgay Simsek; Zeynep Canturk
Journal:  Cancer Genomics Proteomics       Date:  2017 May-Jun       Impact factor: 4.069

2.  The use of positron emission tomography with (11)C-methionine in patients with primary hyperparathyroidism.

Authors:  Filomena Cetani; Claudio Marcocci
Journal:  Endocrine       Date:  2013-02-03       Impact factor: 3.633

3.  The Significance of Histologically "Large Normal" Parathyroid Glands in Primary Hyperparathyroidism.

Authors:  Russel Krawitz; Anthony Glover; Sireesha Koneru; James Jiang; Aimee Di Marco; Anthony J Gill; Ahmad Aniss; Mark Sywak; Leigh Delbridge; Stan Sidhu
Journal:  World J Surg       Date:  2020-04       Impact factor: 3.352

4.  2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer.

Authors:  R Elisei; M Alevizaki; B Conte-Devolx; K Frank-Raue; V Leite; G R Williams
Journal:  Eur Thyroid J       Date:  2012-12-19

5.  Muscle function is impaired in patients with "asymptomatic" primary hyperparathyroidism.

Authors:  Lars Rolighed; Anne Kristine Amstrup; Niels Frederik Breum Jakobsen; Tanja Sikjaer; Leif Mosekilde; Peer Christiansen; Lars Rejnmark
Journal:  World J Surg       Date:  2014-03       Impact factor: 3.352

6.  Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas.

Authors:  Simona Borsari; Elena Pardi; Natalia S Pellegata; Misu Lee; Federica Saponaro; Liborio Torregrossa; Fulvio Basolo; Elena Paltrinieri; Maria Chiara Zatelli; Gabriele Materazzi; Paolo Miccoli; Claudio Marcocci; Filomena Cetani
Journal:  Endocrine       Date:  2016-04-02       Impact factor: 3.633

Review 7.  Single-cell approaches for molecular classification of endocrine tumors.

Authors:  James Koh; Nancy L Allbritton; Julie A Sosa
Journal:  Curr Opin Oncol       Date:  2016-01       Impact factor: 3.645

Review 8.  Update on parathyroid carcinoma.

Authors:  F Cetani; E Pardi; C Marcocci
Journal:  J Endocrinol Invest       Date:  2016-03-21       Impact factor: 4.256

9.  Analyzing Genetic Differences Between Sporadic Primary and Secondary/Tertiary Hyperparathyroidism by Targeted Next-Generation Panel Sequencing.

Authors:  Yu Ah Hong; Ki Cheol Park; Bong Kyun Kim; Jina Lee; Woo Young Sun; Hae Joung Sul; Kyung-Ah Hwang; Won Jung Choi; Yoon-Kyung Chang; Suk Young Kim; Soyoung Shin; Joonhong Park
Journal:  Endocr Pathol       Date:  2021-07-03       Impact factor: 3.943

10.  Genetic and clinical features of multiple endocrine neoplasia types 1 and 2.

Authors:  C Romei; E Pardi; F Cetani; R Elisei
Journal:  J Oncol       Date:  2012-11-08       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.